ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LKFT / options
PVLA (45) IMNM (26) PRGO (49) SEPN (63) ⌘ Pro Terminal →

Lakefront Biotherapeutics (LKFT) Options Positioning, Max Pain & Unusual Sweeps

$32.02 -0.80% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $31.91

Lakefront Biotherapeutics (LKFT) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $2.13B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LKFT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LKFT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Lakefront Biotherapeutics (NASDAQ: LKFT) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $32.02 (-0.80% 1D, market cap $2.13B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, LKFT ranks #190 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LKFT compare to PVLA and IMNM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LKFT carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PVLA (Palvella Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -27.9%, cap $2.11B) and IMNM (Immunome Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $2.15B). Among the 5-stock peer group, LKFT leads on earnings multiple (N/A) while PRGO leads on capital efficiency (-13.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LKFT?
▼

For Lakefront Biotherapeutics (LKFT), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #190 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $31.91 (-0.33%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510057
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D+ · Rk C-
Cash (12)Whales (12)SEC (13)Macro (11)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-0.4% Base Target
$38 Bull$32 Base$25 Bear
📬 FREE LKFT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LKFT)Realized 20D OHLCV Swing Band: ±4.8%
Deterministic 5-Pillar Attribution (57/100 Composite)
🔍 WHY LKFT SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (21% of score)

SEC XBRL Trailing 12 Months: 1.5% FCF Margin ($59.6M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
49
Grade D$29.05+5.9% Next Q
Q2 (-2Q)
52
Grade C-$30.75+3.5% Next Q
Q3 (-1Q)
54
Grade C-$31.82+0.6% Next Q
Current
57
Grade D+$32.02-0.2% Hist 90D α
Trajectory: D (49) → D+ (57)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LKFT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, LKFT faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($29.62) or 200D SMA ($29.91) invalidates the momentum regime and cuts Target Base ($31.88) toward Bear Floor ($24.87).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LKFT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LKFT Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 57%NO 43%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±4.8%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (LKFT)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for LKFT.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LKFT)

  • ✓Walkthrough of LKFT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LKFT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.51%▲ ASCENDING CHANNEL
2026-11-03O $32.33H $32.33L $32.02C $32.02VOL 164.1K
RES: $33.25SUP: $27.86SMA50: $29.62SMA200: $29.91
$33.26$31.20$29.15$27.10$25.04RES $33.25SUP $27.86$32.022026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LKFT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LKFT Butterfly Map → + Track LKFT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LKFT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LKFT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LKFT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LKFT)

Health Care Rank #190 of 1015 ⚔️ PVLA vs LKFT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LKFT vs. PVLA, IMNM, PRGO, SEPN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Lakefront Biotherapeutics (LKFT) ranks #190 by composite RQD confidence (57/100, grade D+) and #244 by equity capitalization ($2.13B). Within this direct 5-issuer industry benchmark cohort, LKFT leads on earnings valuation at N/A trailing P/E, while PRGO leads on capital efficiency and profitability with -13.6% ROIC and 35.1% gross margin. SEPN currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with LKFT at 57/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LKFT ACTIVE
Lakefront Biotherapeutics
D+ 57/100 — — — -0.80% $2.13B Benchmark Subject
PVLA
Palvella Therapeutics Inc.
D 45/100 — — -27.9% +0.12% $2.11B /pvla-vs-lkft →
IMNM
Immunome Inc.
E 26/100 — — -35.0% +7.58% $2.15B /imnm-vs-lkft →
PRGO
Perrigo Company plc
D 49/100 — 35.1% -13.6% -0.19% $2.19B /prgo-vs-lkft →
SEPN
Septerna Inc.
C 63/100 — — -20.7% -1.82% $2.05B /sepn-vs-lkft →

2. LKFT Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Lakefront Biotherapeutics (LKFT) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $2.13B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. LKFT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LKFT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Lakefront Biotherapeutics (NASDAQ: LKFT) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $32.02 (-0.80% 1D, market cap $2.13B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, LKFT ranks #190 in composite RQD confidence.

How does LKFT compare to PVLA and IMNM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LKFT carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PVLA (Palvella Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -27.9%, cap $2.11B) and IMNM (Immunome Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $2.15B). Among the 5-stock peer group, LKFT leads on earnings multiple (N/A) while PRGO leads on capital efficiency (-13.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LKFT?

For Lakefront Biotherapeutics (LKFT), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #190 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LKFT trading relative to its 50-day, 200-day, and 52-week technical levels?

LKFT last traded at $32.02 (-0.80% on volume of 259,068 shares), positioning the stock +8.10% above its 50-day simple moving average ($29.62) and +7.05% above its 200-day simple moving average ($29.91). Across its 52-week range of $25.68 to $36.24, LKFT sits at the 60.0% percentile with a 14-day RSI of 69.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.8% ($30.48 to $33.56).

Direct Sub-Reports: LKFT RQD Cockpit LKFT 12M Forecast LKFT Earnings & Move LKFT Dividends & DRIP LKFT Insiders & 13F LKFT Whale Options LKFT Profit Sankey LKFT News & Why
ROARABLE RATING BRIEF • RQD 57/100 (D+) ✓ SEC XBRL & RQD VERIFIED

LKFT — Lakefront Biotherapeutics: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Lakefront Biotherapeutics (LKFT) earns a live Roarable RQD composite score of 57/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $32.02 (-0.80% 1D, market capitalization $2.13B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (12/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Lakefront Biotherapeutics (LKFT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The profile reports a market capitalization of $2.1B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 57/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 12/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $25.68 – $36.24 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream/downstream dependencies, sector correlations, or 2nd-order bottlenecks.

  • Key Question #1: Can LKFT sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $36.24 52-week high?
  • Key Question #3: How sensitive is LKFT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LKFT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lakefront Biotherapeutics (LKFT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LKFT Debate Forum (3) ↓
🟡 MARKET WIRE GlobeNewswire • 1d ago
Acquisition of Own Shares

GlobeNewswire report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LKFT Bull vs. Bear Conversation Board — What's Your Call at $32.02?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LKFT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LKFT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $38.41 (+19.0%)
📌 Pinned Debate

Per the news wire, a Buy upgrade for the sponsored ADR is listed as a green-light catalyst.

Don't sleep on LKFT's setup in Health Care. Per the news wire, a Buy upgrade for the sponsored ADR is listed as a green-light catalyst.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (57/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $26.47 (-18.0%)
Spot @ $32.28

Per the RQD rating, the Fundamental Cash Engine pillar shows 0% ROIC and 0% FCF yield with an overall grade of D+.

Here is the bear case nobody on the bull side wants to address on LKFT: Per the RQD rating, the Fundamental Cash Engine pillar shows 0% ROIC and 0% FCF yield with an overall grade of D+.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE